Annual Report 2022

Department of Dermatologic Oncology

Akira Takahashi, Shunichi Jinnai

Introduction

 The Department of Dermatologic Oncology began full time practice in April 2022 with two dermatologists. The department provides surgical treatment and chemotherapy for cutaneous malignancies, as well as supportive care for skin disorders associated with the treatment of carcinomas in other departments.

The Team and What We Do

 The department has two staff dermatologic oncologists. In FY2022, there were a total of 112 new cases of major skin cancers, including 44 cases of malignant melanoma, 16 cases of squamous cell carcinoma, 14 cases of extra-mammary Paget disease, etc. The number of surgeries and the number of patients treated with immune checkpoint inhibitors and other drugs in FY2022 are shown in Tables 1 and 2, respectively. In addition, the number of first-time supportive care patients with skin disorders associated with cancer treatment was 650. Moreover, we have treated patients with advanced cases of mucosal melanoma in the nasal cavity, genital lesion, perianal lesions and uveal melanoma, although our origins are dermatologic.

Research Activities

 The Department of Dermatologic Oncology is a member of the Japan Clinical Oncology Group (JCOG) Dermatologic Oncology Group and participates in multicenter collaborative studies.

• Confirmatory trial of non-amputative digit preservation surgery for subungual melanoma. (JOCG1602)
• Confirmatory trial of narrower side margins for basal cell carcinoma in Japanese population. (JCOG2005)

Education

 Dr. Shunichi Jinnai was recruited from Chief Resident of National Cancer Center Hospital to join our staff of Dermatologic Oncology in April 2022.

 From 2023, we will accept residents and train them to be internationally active in the central position of skin malignancy treatment in Japan.

Future Prospects

 It has been suggested that the therapeutic efficacy of immune checkpoint inhibitors differs between Westerners and Asians, thus, establishing Japanese-specific evidence in treatment strategies is necessary. Furthermore, little evidence is found for the treatment of rare skin cancers such as angiosarcoma, extramammary Paget's disease, and Merkel cell carcinoma; thus multicenter collaborative studies are necessary for the development of treatment.

 In addition, few physicians specialize in the treatment of cutaneous malignancies in the field of dermatology, and we will train dermatologic oncologists at our hospital, which is a specialized oncology training facility.

List of papers published in 2022

Journal

1. Hiki K, Ogata D, Hisada I, Sakamoto T, Hiroyuki T, Yamakawa K, Namikawa K, Takahashi A, Saito Y, Yamazaki N. Minimally invasive surgery combined with excision and endoscopic submucosal dissection for anorectal melanoma . The Journal of dermatology, 50:e26-e27 , 2023

2. Yamakawa K, Ogata D, Hiki K, Jinnai S, Namikawa K, Takahashi A, Yamazaki N. Metastatic basal cell carcinoma with a high tumor mutational burden that achieved complete response with pembrolizumab . International journal of dermatology, 62:e79-e80 , 2023

3. Kashihara T, Ogata D, Okuma K, Nakamura S, Nakayama H, Mori T, Takahashi A, Namikawa K, Takahashi A, Takahashi K, Kaneda T, Inaba K, Murakami N, Okamoto H, Nakayama Y, Yamazaki N, Igaki H. Clinical significance of local control of primary tumour in definitive radiotherapy for scalp angiosarcomas . Skin research and technology, 29:e13243 , 2023

4. Ishiguro A, Ogata D, Okuma K, Kashihara T, Murakami N, Hiki K, Yamakawa K, Jinnai S, Takahashi A, Namikawa K, Igaki H, Yamazaki N. Malignant melanoma treatment using brachytherapy: Two case reports and 15 case series . The Journal of dermatology, 50:94-97 , 2023

5. Ogata D, Tsutsui K, Namikawa K, Moritani K, Nakama K, Jinnai S, Takahashi A, Tsukamoto S, Kanemitsu Y, Yamazaki N. Treatment outcomes and prognostic factors in 47 patients with primary anorectal malignant melanoma in the immune therapy era . Journal of cancer research and clinical oncology, 149:749-755 , 2023

6. Mizuta H, Ogata D, Jinnai S, Namikawa K, Takahashi A, Yamazaki N. Pathological complete response to preoperative avelumab treatment in a patient with advanced Merkel cell carcinoma. Dermatology online journal, 28:2022

7. Okumura M, Nakano E, Namikawa K, Takahashi A, Fujiwara Y, Yamazaki N. Efficacy of surgery for skin cancers initially suspected to be carcinoma of unknown primary: a retrospective observational study . International journal of dermatology, 61:e150-e152 , 2022

8. Jinnai S, Namikawa K, Takahashi A, Ogata D, Yamazaki N. Incidence and patterns of lymphatic drainage to the epitrochlear and popliteal sentinel lymph nodes in malignant melanoma of the distal extremities: a single-institution retrospective study . International journal of dermatology, 61:855-860 , 2022

9. Kamimura A, Nakamura Y, Takenouchi T, Matsushita S, Omodaka T, Yamamura K, Uchi H, Yoshikawa S, Yanagisawa H, Ito T, Kiyohara Y, Nakamura Y, Aoki M, Ishizuki S, Oashi K, Miyagawa T, Maeda T, Ogata D, Hatta N, Ohe S, Isei T, Takahashi A, Umeda Y, Yamaguchi B, Ishikawa M, Horimoto K, Fujsawa Y, Uehara J, Shibayama Y, Kiniwa Y, Kawahara Y, Matsuya T, Uhara H, Kato J, Nakamura Y, Murakami T, Namikawa K, Yoshino K, Funakoshi T, Takatsuka S, Matsui Y, Sasaki J, Koga H, Yokota K, Komori T, Fukushima S, Yamazaki N. Concordance in judgment of clinical borders of basal cell carcinomas in Japanese patients: A preliminary study of JCOG2005 (J-BASE-MARGIN) . The Journal of dermatology, 49:837-844 , 2022

10. Ishiguro A, Ogata D, Ohashi K, Hiki K, Yamakawa K, Jinnai S, Tsutsui K, Takahashi A, Namikawa K, Yamazaki N. Type 1 diabetes associated with immune checkpoint inhibitors for malignant melanoma: A case report and review of 8 cases . Medicine, 101:e30398 , 2022

11. Okumura M, Ogata D, Namikawa K, Tsutsui K, Takahashi A, Okuma K, Kashihara T, Igaki H, Akiyama M, Yamazaki N. Postoperative radiation therapy improves prognoses in extramammary Paget's disease presenting with multiple lymph node metastases . The Journal of dermatology, 49:1005-1011 , 2022